The landscape of hepatobiliary oncology is currently undergoing a period of profound transformation. As researchers decode the complex molecular architecture of aggressive malignancies, the clinical community faces an urgent imperative: to translate these laboratory breakthroughs into tangible, bedside patient benefits. In a strategic move to centralize this evolving knowledge, Expert Review of Gastroenterology & Hepatology has officially announced an upcoming "Article Collection" dedicated to the prevention, diagnosis, and treatment of biliary cancers.
This initiative serves as a clarion call to the global scientific community, inviting oncologists, hepatobiliary surgeons, and multidisciplinary specialists to contribute their latest findings. By aggregating high-impact research, the journal aims to establish a definitive reference point for the management of cholangiocarcinoma and gallbladder cancer—two of the most formidable challenges in modern oncology.
Main Facts: A Focus on Aggressive Malignancies
Biliary tract cancers (BTCs), encompassing both cholangiocarcinoma and gallbladder carcinoma, have long been categorized as "orphan" diseases with high mortality rates and limited therapeutic options. Characterized by their aggressive biological behavior and late-stage presentation, these cancers represent a critical area of unmet medical need.
The upcoming collection by Expert Review of Gastroenterology & Hepatology is designed to bridge the gap between bench-side molecular profiling and clinical practice. The scope of the collection is deliberately expansive, encompassing:
- Molecular Profiling and Biomarkers: Moving beyond generic staging to embrace precision oncology.
- Surgical Innovation: Highlighting advancements in minimally invasive procedures and complex resections that offer curative potential.
- Systemic Therapies: Exploring the evolving roles of immunotherapy, targeted small-molecule inhibitors, and novel chemotherapy regimens.
- Early Detection Strategies: Investigating the use of liquid biopsies and imaging advancements to intercept disease progression at more treatable stages.
By focusing on these pillars, the journal seeks to move the needle from palliative care toward curative or chronic management strategies, significantly extending the quality and duration of life for affected patients.
Chronology: The Evolution of Biliary Cancer Care
The historical trajectory of biliary cancer treatment has been marked by stagnation, followed by a recent, rapid acceleration of innovation.
The Era of "Standard of Care" Limitations (Pre-2015)
For decades, the standard of care for advanced biliary tract cancer remained largely unchanged: systemic gemcitabine plus cisplatin. While this regimen provided a baseline for survival, it was frequently associated with significant toxicity and modest response rates. During this period, biliary cancer was often perceived as a "stiff" disease, resistant to many conventional therapeutic approaches.
The Molecular Revolution (2015–2020)
The advent of next-generation sequencing (NGS) fundamentally altered the field. Researchers began identifying specific genomic drivers, such as FGFR2 fusions, IDH1 mutations, and HER2 amplifications. This shift in understanding allowed for the categorization of BTCs into distinct molecular subtypes, each requiring a tailored approach.
The Age of Precision Oncology (2020–Present)
Recent years have seen the FDA approval of several targeted therapies for biliary tract cancers, marking a historic shift. The integration of checkpoint inhibitors, such as durvalumab, into standard first-line regimens has demonstrated improved overall survival, signaling that the "one-size-fits-all" era is effectively over. The current call for papers by Taylor & Francis arrives at the peak of this momentum, aiming to document the next wave of these life-altering developments.
Supporting Data: The Clinical Imperative
The necessity for this collection is underscored by the epidemiological realities of biliary cancer. While once considered rare, the incidence of intrahepatic cholangiocarcinoma has been steadily rising globally over the last three decades.
Epidemiological Burden
Recent global cancer statistics indicate that biliary tract cancers account for approximately 3% of all gastrointestinal cancers, but their mortality-to-incidence ratio remains disproportionately high. Because many patients present with non-specific symptoms—jaundice, abdominal pain, or weight loss—the disease is often advanced at the time of diagnosis, rendering radical surgical resection impossible for the majority.
The Impact of Multidisciplinary Care
Data consistently demonstrates that outcomes for BTC patients are significantly improved when managed within a high-volume multidisciplinary tumor board. Studies have shown that patients reviewed by a team consisting of surgeons, medical oncologists, interventional radiologists, and pathologists have higher rates of R0 resection and better access to clinical trials. The upcoming Article Collection aims to formalize these multidisciplinary strategies, providing a roadmap for institutions worldwide to replicate these successful care models.
Official Responses and Editorial Vision
The commissioning team at Expert Review of Gastroenterology & Hepatology emphasizes that this collection is not merely an academic exercise, but a strategic effort to influence clinical policy and practice.
Commissioning Editor Olivia Clovis-Corbett highlights the importance of inclusivity in this submission process. "We are looking for a diverse range of contributions," Clovis-Corbett noted. "Whether it is a comprehensive review of the current state of immunotherapy, an original research paper detailing a novel biomarker, or a short editorial exploring the challenges of access to care, we want to hear from the experts who are on the front lines of patient treatment."
The editorial board of the journal has signaled that submissions will be prioritized based on their potential to impact patient management. They are particularly interested in "translational" work—studies that take a finding from the molecular level and clearly demonstrate its utility in a clinical setting.
Implications: The Future of Biliary Cancer Management
The long-term implications of this project are twofold: clinical and systemic.
Improving Patient Outcomes
By disseminating evidence-based strategies, the journal intends to reduce the variability in care that currently exists between different geographical regions and hospital settings. When clinicians are equipped with the latest data on molecular profiling and surgical techniques, the standard of care is elevated globally.
Driving Future Research
This Article Collection will serve as a foundational document for the next five years of research. By identifying gaps in current knowledge—such as the mechanisms of resistance to current targeted therapies—it will steer future clinical trials toward the most promising avenues of exploration.
A Call to Action
For the research community, this is a unique opportunity to contribute to a seminal collection that will be read by the world’s leading gastroenterologists and hepatologists. The journal is accepting a variety of submission formats, including:
- Reviews: Summarizing the current state of the art.
- Original Research: Presenting primary data from clinical trials or translational studies.
- Drug Profiles: Detailed analyses of new pharmacological agents.
- Editorials: Opinion pieces on the future directions of the field.
As the medical community continues to peel back the layers of complexity surrounding hepatobiliary malignancies, the importance of collaborative knowledge-sharing cannot be overstated. Through this initiative, Taylor & Francis is providing the infrastructure for that collaboration, ensuring that the next generation of biliary cancer patients benefits from the collective wisdom and innovation of the global scientific community.
For those interested in contributing their expertise, the commissioning editor is actively available to discuss proposals, ensuring that the final collection is as robust, diverse, and impactful as possible. This is more than a call for papers; it is a call for a new standard of care in the fight against biliary cancer.
Interested parties are invited to find out more or contact the Commissioning Editor, Olivia Clovis-Corbett, to discuss potential submissions.
About the Author
